Aveva Drug Delivery Systems, Inc. – Trademark Portfolio
Entity Type: 03
Aveva Drug Delivery Systems, Inc. holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 6 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include AVEVA. The owner is based in Miramar, FL.
3250 Commerce Parkway
Miramar, FL 33025
Showing of trademarks Trademarks
Trademark Classifications
Aveva Drug Delivery Systems, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Aveva Drug Delivery Systems, Inc. have?
Aveva Drug Delivery Systems, Inc. has 6 U.S. trademarks filed with the USPTO. Of these, 2 registered, 3 abandoned, 1 cancelled.
What trademark classes does Aveva Drug Delivery Systems, Inc. file in?
Aveva Drug Delivery Systems, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 40 (Treatment & Processing). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Aveva Drug Delivery Systems, Inc.'s most well-known trademarks?
Aveva Drug Delivery Systems, Inc.'s registered trademark portfolio includes well-known marks such as AVEVA. These are among 2 currently registered trademarks in the portfolio.
What is Aveva Drug Delivery Systems, Inc.'s trademark registration success rate?
Aveva Drug Delivery Systems, Inc. has a 33% trademark registration rate, with 2 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.